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Our understanding of keratoconjunctivitis sicca (KCS), also known as dry eye 
syndrome, has been changed over recent years. Until lately, the condition was thought 
to be merely due to aqueous tear insufficiency. Today, it is understood that KCS is a 
multifactorial disorder due to inflammation of the ocular surface and lacrimal gland, 
neurotrophic deficiency and meibomian gland dysfunction. This change in paradigm 
has led to the development of new and more effective medications.
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INTRODuCTION
Dry eye is a disorder of the tear film which 
occurs due to tear deficiency or excessive 
tear evaporation; it causes damage to the 
interpalpebral ocular surface and is associated 
with a variety of symptoms reflecting ocular 
discomfort.1 Dry eye syndrome, also known as 
keratoconjunctivitis sicca (KCS), is a common 
condition reported by patients who seek 
ophthalmologic care and is characterized by 
inflammation of the ocular surface and lacrimal 
glands.
Dry eye symptoms may be a manifestation 
of a systemic disease, therefore timely detection 
may lead to recognition of a life–threatening 
condition. Additionally, patients with dry eye 
are prone to potentially blinding infections, such 
as bacterial keratitis2 and also at an increased risk 
of complications following common procedures 
such as laser refractive surgery.
Knowledge of the pathophysiology of dry 
eye has recently been improved and the condition 
is now understood to be a multifactorial disease, 
characterized by inflammation of the ocular 
surface and reduction in tear production.3 
This awareness has led to the development of 
highly effective therapies.
EPIDEMIOLOGy
Approximately 1 out of 7 individuals aged 65 to 
84 years reports symptoms of dry eye often or all 
of the time.4 Moss et al5 reported the prevalence 
of dry eye to be 14.4% in 3,722 subjects aged 
48 to 91 years and noted that the prevalence 
of the condition doubled after the age of 59. 
Schein et al4, in contrast, found no correlation 
between dry eye and age or sex, while other 
researchers have reported such associations to 
exist. A study on 926 subjects aged 40 years 
and older, found a higher prevalence of dry 
eye in women who were also more likely to 
have a dry eye-related diagnosis or procedure.6 
According to another study, women experienced 
a sharp increase in the prevalence of dry eye 
earlier than men, around the age of 45, roughly 
at the onset of menopause.7
Epidemiological studies on dry eye 
syndrome suggest vast differences in prevalence. 
The difficulty in determining the extent of 
the disease stemmed in part from limited Dry Eye Syndrome; Javadi and Feizi
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understanding of the pathophysiology of dry 
eye. As such, definitions of dry eye syndrome 
differed from one study to another, making 
results difficult to compare.8 This is further 
complicated by the lack of a standardized clinical 
testing protocol to diagnose the condition.
CLINICAL TyPES
The precorneal tear film is an essential component 
of the ocular surface and can be subdivided into 
an anterior lipid layer, a middle aqueous layer 
and an innermost mucin layer. These layers are 
produced by the meibomian glands, the lacrimal 
gland and goblet cells of the conjunctiva, 
respectively.2 The tear film lubricates the eye, 
maintains nutrition and oxygenation of ocular 
structures, acts as a refractive component and 
helps remove debris from the ocular surface. 
In terms of tear production, dry eye can be 
divided into tear deficient and evaporative 
types.3 Tear deficiency dry eye can further be 
subdivided into non-Sjogren syndrome and 
Sjogren syndrome, which is an autoimmune 
disease associated with lacrimal and salivary 
gland lymphocytic infiltration. Evaporative 
dry eye can be divided into meibomian gland 
disease (MGD) and exposure-related dry 
eye.4,5 In yet another group of patients, mucin 
deficiency due to Stevens-Johnson syndrome or 
ocular cicatricial pemphigoid is the underlying 
mechanism of dry eye.8
ETIOLOGy
Dry eye syndrome is associated with a long list 
of causes which can be divided into primary and 
secondary. Dry eye may develop secondary to 
inflammatory disease (e.g. vascular, allergic), 
environmental conditions (e.g. allergens, 
cigarette smoke, dry climate), hormonal 
imbalance (e.g. perimenopausal women and 
patients under hormone replacement therapy), 
and contact lens wear. Systemic disorders, such 
as diabetes mellitus, thyroid disease, rheumatoid 
arthritis and systemic lupus erythematosus can 
also lead to dry eye. In addition, neurotrophic 
deficiency, previous eye surgery (such as 
corneal transplantation, extracapsular cataract 
procedures and refractive surgery), or long-
term use of medications which create hyper-
sensitivity or toxicity in the eye can predispose 
to dry eye. Many systemic medications, such 
as diuretics, antihistamines, antidepressants, 
psychotropics, cholesterol lowering agents, 
beta-blockers and oral contraceptives may also 
be associated with dry eye.9,10
Postmenopausal women may be the 
largest at risk group; this is due to a decrease 
in hormonal levels leading to loss of anti-
inflammatory protection and decreased lacrimal 
secretion.9
PATHOGENESIS 
Studies performed on the proteomic profile of 
the ocular surface comparing dry with normal 
eyes using enzyme-linked immunosorbent assay 
(ELISA) has revealed a decrease in lactoferrin 
and epidermal growth factor in dry eyes. A 
protein found in acinar cells of the lacrimal 
gland, AQP-5, was shown to be increased in the 
Sjogren type of dry eye syndrome, indicating 
possible leakage of such proteins into the tear 
film due to lymphocytic infiltration of the 
lacrimal gland.9 Solomon et al10 found an increase 
in inflammatory cytokines interleukin 1 (IL-1) 
alpha and IL-1 beta in both MGD and Sjogren 
syndrome, indicating increased protease activity 
on the ocular surface, mainly in the conjunctival 
epithelium. Apart from IL-1, IL-6 was also 
increased in Sjogren syndrome,11 indicating an 
inflammatory process in this subgroup of dry 
eye. Another study investigating sialic acid, a 
component of mucin in tears, found a lower 
level in dry eye patients compared to controls, 
indicating a change in quantity and quality of 
tear film glycoproteins in dry eye disease.12 
The change in tear protein profile in dry eye 
syndrome, especially in Sjogren disease, has 
shed light on mechanisms of dry eye.
CLINICAL SyMPTOMS
Symptoms associated with dry eye may include 
ocular burning, foreign body sensation, stinging 
sensation, pain, photophobia and blurred 
vision.9-12Dry Eye Syndrome; Javadi and Feizi
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As dry eye syndrome may be associated with a 
variety of causes, it is important to perform a 
comprehensive evaluation before proceeding to 
treatment. A careful history should be obtained 
with particular attention to diabetes, thyroid 
disease, connective tissue disorders and contact 
lens wear. Previous ocular procedures, such as 
laser refractive surgery are also important in 
determining the cause of dry eye syndrome. 
Many medications can affect tear secretion and 
it is important to review the patient’s drug 
history. A careful clinical examination should 
include slit lamp biomicroscopy to determine 
ocular surface status and diagnose associated 
meibomian gland dysfunction, blepharitis or 
meibomian seborrhoea. Examination of the 
tarsus and fornices for scars and symblepharon 
is important to exclude pre-existing Stevens-
Johnson syndrome, other ocular surface 
inflammatory disease or previous infections. A 
careful look at the conjunctiva and cornea would 
be helpful to assess the severity of dry eye; an 
increase in staining is observed in more severe 
cases. Occasionally, corneal filaments and edema 
may be observed in extremely dry eyes. It is 
important to be thorough in the examination 
to find other areas of involvement. Certain 
systemic causes of dry eye, such as rheumatoid 
arthritis and systemic lupus erythematosus not 
only involve the ocular surface but also cause 
inflammation of the episclera or sclera, and 
occasionally the posterior segment.
DIAGNOSTIC CRITERIA
Ohashi et al9 suggested that a combination of (1) 
dry eye symptoms, (2) suggestive findings on 
Schirmer (< 5 mm wetting after 5 minutes) and 
fluorescein clearance tests, and (3) fluorescein 
and Rose Bengal staining (> 3+) would verify 
clinical dry eye. Other authors have devised 
different diagnostic criteria and there is 
no consensus in this regard.13-15 To further 
complicate the issue, symptoms and signs do 
not always correlate well with each other in 
many patients.14
To confirm a diagnosis of dry eye, certain 
tests are required in the clinical setting. Tear 
film stability can be assessed with the fluorescein 
tear break-up time test (TBUT). This measures 
the interval in seconds between a complete 
blink and the first appearance of a dry spot or 
discontinuity in the precorneal film. Patients 
with TBUT less than 3 seconds are classified 
with clinical dry eye. If there is aqueous 
deficiency, the tear meniscus will appear to be 
thin, less than 1 mm in height. Another clinical 
method for assessing the severity of dry eye 
is ocular surface dye staining. Fluorescein and 
Rose Bengal stains can be used as diagnostic 
dyes. Fluorescein staining occurs when the 
epithelial barrier is disrupted and serves as 
a good test for evaluation of dry eye. Rose 
Bengal stains devitalized epithelial cells on 
the conjunctiva and serves a similar purpose. 
However, Rose Bengal causes transient irritation 
after instillation and may be less comfortable. 
Patients with dry eye syndrome can show signs 
of punctate epitheliopathy and even corneal 
abrasions.
Another important clinical test is the 
Schirmer test which measures aqueous tear 
production. This test is easy to perform in 
clinical settings but may be subject to errors. 
Strips of filter paper, called Schirmer strips, 
are placed on the lower lid inside the tarsal 
conjunctiva. The patient is allowed to blink 
normally and the tear strip is scored according 
to the degree it wets in 5 minutes. There are two 
ways to perform this test: (a) without topical 
anesthesia (Schirmer test I) which evaluates 
the ability of the ocular surface to respond 
to surface stimulation; and (b) under topical 
anesthesia (Schirmer test II) which evaluates 
basal tear secretion. Patients with tear soaking 
less than 10 mm are considered to have clinical 
dry eye and eyes with less than 5 mm wetting 
are diagnosed as severely dry. However, it is 
important to note that Schirmer tests are subject 
to environmental and physiologic changes with 
varying results over time.
MANAGEMENT 
Management of dry eye depends on the cause 
and severity of the condition. Artificial tears are Dry Eye Syndrome; Javadi and Feizi
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used to replenish the deficient aqueous layer 
of the tear film and to dilute inflammatory 
cytokines. Artificial tears are available in 
different viscosities and preserved or non-
preserved preparations. If the tear deficiency 
is severe, more viscous agents such as gels 
or ointments can be used to maintain longer 
protection. Since KCS, including Sjogren 
syndrome, is associated with inflammation, 
the use of topical steroids or non-steroidal 
anti-inflammatory medications is sometimes 
helpful. Topical antibiotics may be necessary 
if the dry eye syndrome is associated with 
corneal complications. Meibomian gland disease 
warrants prescription of eyelid hygiene and 
warm lid compresses, together with topical or 
even systemic antibiotics such as doxycycline.13,14
For more severe disease, topical immuno-
modulating agents, such as cyclosporine-A 
drops, may become necessary. Studies have 
demonstrated an improvement in signs and 
symptoms of dry eye, together with reduction in 
conjunctival T-cell infiltration and tear cytokine 
levels following the use of cyclosporine-A 
drops.15,16
In very severe cases, frequent topical 
lubricants may not suffice. Studies have looked 
into the use of autologous serum as topical eye 
drops for severely dry eyes with improvement 
reported after prolonged treatment regimens 
ranging from 4 to 6 weeks. Growth factors 
provided by autologous serum are important 
for epithelial healing. Autologous serum can 
be prepared by centrifuging venous blood and 
diluting it with balanced salt solution to 20%.17
Bandage contact lenses are sometimes useful 
in dry eyes to minimize the extent of exposure 
keratopathy. Severe dry eye disease with corneal 
complications may warrant surgical intervention 
such as punctal occlusion. Lacrimal puncta 
can be plugged temporarily with absorbable 
collagen plugs or for a longer period of time 
with non-absorbable plugs which need to be 
removed if problems arise. Permanent punctal 
occlusion can also be performed to prevent tears 
from draining through the drainage system. For 
patients with dry eye secondary to connective 
tissue disease, it is important to collaborate with 
internists and optimize treatment for the systemic 
disorders. In very severe dry eye secondary 
to ocular surface disease (such as chemical 
injury, Stevens-Johnson syndrome, or ocular 
cicatricial pemphigoid), amniotic membrane 
transplantation, tarsorrhaphy, keratoplasty, 
limbal stem cell transplantation, or even ocular 
prostheses, such as rigid scleral contact lenses, 
may become necessary for restoration of vision.18 
Anti-Inflammatory Therapy
Before recent findings reframed our 
understanding of dry eye, treatment was 
limited to the use of artificial tears, ointments, 
and non-pharmacologic therapies, such as 
punctal occlusion, environmental control, 
moisture-retaining eyewear, and surgery. Each 
had limited efficacy and few resulted in long-
lasting improvement in patients’ quality of life. 
Today, dry eye can be treated successfully with 
anti-inflammatory agents, the most beneficial of 
which is topical cyclosporine. Clinical evidence 
indicates that anti-inflammatory therapy inhibits 
the production of inflammatory mediators and 
reduces the signs and symptoms of KCS.
Corticosteroids
Corticosteroids are potent anti-inflammatory 
agents routinely used to control inflammation 
in various organs. Corticosteroids have multiple 
mechanisms of action. They work through 
traditional glucocorticoid receptor mediated 
pathways which directly regulate gene 
expression and also by non-receptor pathways 
that interfere with transcriptional regulators of 
pro-inflammatory genes. Among their multiple 
biological activities, corticosteroids inhibit the 
production of inflammatory cytokines and 
chemokines, decrease the synthesis of matrix 
metalloproteinases and lipid mediators of 
inflammation (e.g. prostaglandins), reduce 
the expression of cell adhesion molecules (e.g. 
intercellular adhesion molecule 1), and stimulate 
lymphocyte apoptosis.19-21 Steroids have been 
reported to decrease the production of a number 
of inflammatory cytokines, including IL-1, IL-6, 
IL-8, tumor necrosis factor-alpha (TNF-α), and 
granulocyte macrophage colony-stimulating Dry Eye Syndrome; Javadi and Feizi
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factor (GM-CSF), and matrix metalloproteinase 
9 (MMP-9) by the corneal epithelium.22 
Corticosteroids have been successfully used 
for treatment of corneal epithelial disease due 
to dry eye in several clinical studies.23-25 
Cyclosporine
Cyclosporine A (CsA) is a lipophilic cyclic 
undecapeptide isolated from the fungus 
Hypocladium inflatum gams.26 It was first 
introduced for clinical use as an immune-
suppressant drug for prevention of organ 
transplant rejection in 1983. The immuno 
modulatory effect of this agent has been 
proven to be beneficial for treatment of a 
broad range of disorders such as psoriasis, 
rheumatoid arthritis and ulcerative colitis 
which have an underlying inflammatory basis. 
One of its mechanisms of action is inhibition 
of calcineurin, a serine/threonine phosphatase, 
with subsequent reduction in the expression 
of certain genes involved in T-cell activation 
such as IL-2, IL-4, IL-12.
The potential of CsA for treating dry eye 
disease has been demonstrated in several 
randomized double-masked clinical trials.27-29 
Tetracyclines and their Derivatives
The tetracyclines have anti-inflammatory, 
as well as antibacterial, properties that may 
make them useful for management of chronic 
inflammatory diseases. These agents decrease 
the activity of collagenase, phospholipase A2, 
and several matrix metalloproteinases. They 
also decrease the production of IL-1α and 
TNF-α in a wide range of tissues, including the 
corneal epithelium.30-32 At high concentrations, 
tetracyclines inhibit staphylococcal exotoxin-
induced cytokines and chemokines.33,34 
Tetracyclines are also known to inhibit matrix 
metalloproteinase expression, suggesting a 
rationale for their use in ocular rosacea.35 
They can also inhibit angiogenesis, which may 
develop in rosacea. 
Doxycycline was discovered in the 
early 1960s. It is a semisynthetic long-acting 
tetracycline derivative which inhibits bacterial 
ribosomes in a wide variety of micro-organisms. 
In subantimicrobial doses it is also effective 
as primary treatment for rosacea and sterile 
corneal ulceration.36,37 Previous studies using 
experimental dry eye models demonstrated 
that doxycycline was efficacious in decreasing 
gelatinolytic activity in the ocular surface 
epithelia, as well as decreasing levels of MMP-9 
mRNA transcripts, and preventing experimental 
dry eye-induced increase in IL-1 and TNF-α.38 
Doxycycline also improves corneal surface 
regularity and barrier function.39 
Essential Fatty Acids
Essential fatty acids are necessary for health. 
They cannot be synthesized by vertebrates and 
must be obtained from dietary sources. Among 
the essential fatty acids are the 18 carbon omega-6 
and omega-3 fatty acids. In a typical western 
diet, omega-6 fatty acids are consumed 20 to 25 
times more than omega-3 fatty acids. Omega-6 
fatty acids are precursors of arachidonic acid 
and certain pro-inflammatory lipid mediators 
such as prostaglandin E2 and leukotriene B4. In 
contrast, certain omega-3 fatty acids, such as 
eicosapentaenoic acid found in fish oil, inhibit 
synthesis of these lipid mediators and also 
block the production of IL-1 and TNF-α.40,41 A 
beneficial clinical effect from fish oil omega-3 
fatty acids on rheumatoid arthritis has been 
observed in several double-masked placebo-
controlled clinical trials.42,43 In a prospective 
placebo-controlled clinical trial, linoleic acid and 
gamma-linoleic acid administered orally twice 
a day led to significant improvement in ocular 
irritation symptoms, and a reduction in ocular 
surface lissamine green staining conjunctival 
HLA-DR reactivity.44 In an animal model of 
induced dry eye, topical treatment with alpha-
linolenic acid significantly decreased corneal 
fluorescein staining as compared to both vehicle 
and untreated controls, decreased CD11b(+) 
cells and reduced the expression of corneal 
IL-1α and TNF-α, and conjunctival TNF-α.45
CONCLuSIONS
Dry eye syndrome consists of a wide Dry Eye Syndrome; Javadi and Feizi
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spectrum of disorders with different causes. 
Clinicians should be aware of the extent of 
dry eye symptoms. A thorough history and 
investigation is necessary to identify the cause 
of dry eye. Useful clinical tests for assessing 
the severity of the condition include Schirmer, 
fluorescein dye, and tear break up time tests. 
Management depends on an accurate diagnosis 
and the severity of the condition. Treatments 
that replenish deficient tears include artificial 
tears, gels and ointments in mild to moderate 
disease. Other treatment modalities such as 
topical steroids, immunomodulating drugs, 
antibiotics, bandage contact lenses, autologous 
serum and amniotic membrane transplantation 
may be used in more severe cases. In severely 
dry eyes, surgical intervention such as punctal 
occlusion can be employed to minimize tear 
drainage. Certain conjunctival and lid operations 
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